Scientists at the Medical Research Council's National Institute
for Medical Research (NIMR; now part of the Francis Crick
Institute) have unexpectedly discovered that protective immunity to
malaria is not necessarily specific to one lifecycle stage of the
parasite.
The research changes how we think about malaria immunity and
opens up new avenues for vaccine research.
The study was carried out by Wiebke Nahrendorf in Jean
Langhorne's laboratory at NIMR. She explained: "Protection against
malaria can be achieved by repeatedly exposing human volunteers to
the bites of mosquitoes infected with the malaria
parasite, Plasmodium, while treating them with the
antimalarial drug chloroquine. This is known as 'chemoprophylaxis
and sporozoites' (CPS).
"Chloroquine does not interfere with the normal development of
malaria parasites in the skin and liver and only targets the
parasites once they reach the bloodstream. It is therefore unclear
in this immunisation regimen which lifecycle stage is the source
and target of antimalarial immunity."
To investigate, the researchers worked with Robert Sauerwein
from Radboud University Medical Center in Nijmegen, The
Netherlands. Together they developed a new mouse model of CPS
immunisation. They immunised mice using a protocol similar to that
used for human CPS vaccination, using mosquitoes infected with a
malaria parasite that infects mice, and then treated the mice with
chloroquine. It is assumed that his type of immunisation induces
immunity specifically against parasites that develop in the liver
from the injected sporozoites.
However, with the low doses of sporozoites injected by the
mosquito in this model, the researchers found that there was no
immunity against liver-stage parasites. Instead, immunity only
occurred when very large numbers of sporozoites were injected
directly into the bloodstream.
The fact that immunity against liver-stage parasites is only
acquired after injection of high doses of sporozoites may explain
why there is little evidence of immunity against this stage of
infection in areas where malaria occurs naturally and why people
get repeatedly infected by mosquito bites.
Although CPS immunisation does not protect against the liver
stage of the infection, the very short exposure to blood-stage
parasites during the immunisation process does induce immunity to
blood-stage malaria parasites. Importantly a blood-stage infection
induces protective immunity against both blood and stage
liver-stages. These results demonstrate for the first time that
immunity to malaria is not necessarily specific for a particular
life-cycle stage. Instead antigens, which are shared between the
different life-cycle stages of the malaria parasite mediate
cross-stage immunity.
Dr Langhorne said: "The existence of strong
protection against multiple stages of the malaria parasite will
redefine how we think about immunity to this complex parasitic
disease and will open up new avenues for developing multi-stage
malaria vaccines."
The paper, Blood-stage immunity to Plasmodium chabaudi malaria following
chemoprophylaxis and sporozoite immunization, is published ineLife.